Tat peptide-calmodulin binding studies and bioinformatics of HIV-1 protein-calmodulin interactions

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 7, 2011, Pages 2233-2246

  Mcqueen, Peter ^a   Donald, Lynda J ^a   Vo, Thach N ^a   Nguyen, Dung H ^a   Griffiths, Heather ^a   Shojania, Shaheen ^a   Standing, Kenneth G ^a   O'Neil, Joe D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bioinformatics; Calmodulin; Cell cycle; Circular dichroism; Fluorescence; Human immunodeficiency virus; Mass spectrometry; Melittin; NMR spectroscopy; Transactivator of transcription

Indexed keywords

AGAROSE; CALCIUM; CALMODULIN; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; MASTOPARAN; MELITTIN; NEF PROTEIN; PENETRATIN; PEPTIDES AND PROTEINS; PROTEIN P1; PROTEIN P10; PROTEIN P17; PROTEIN P31; PROTEIN P66; PROTEIN VP22; PROTEOME; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS PROTEIN; VPU PROTEIN;

ALGORITHM; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOINFORMATICS; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; FLUORESCENCE ANALYSIS; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; CALMODULIN; CIRCULAR DICHROISM; COMPUTATIONAL BIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MASS SPECTROMETRY; MELITTEN; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79958767263     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.23048     Document Type: Article

References (120)

1. Hoeflich KP, Ikura M. Calmodulin in action: diversity in target recognition and activation mechanisms. Cell 2002; 108: 739-742.
2. Shen XC, Valencia CA, Szostak JW, Dong B, Liu RH. Scanning the human proteome for calmodulin-binding proteins. Proc Natl Acad Sci USA 2005; 102: 9734-9734.
3. Ishida H, Vogel HJ. Protein-peptide interaction studies demonstrate the versatility of calmodulin target protein binding. Protein Pept Lett 2006; 13: 455-465.
4. Bahler M, Rhoads A. Calmodulin signaling via the IQ motif. FEBS Lett 2002; 513: 107-113.
5. Dyer MD, Murali TM, Sobral BW. The landscape of human proteins interacting with viruses and other pathogens. PLOS Pathogens 2008; 4: 1-14.
6. Micoli KJ, Pan G, Wu Y, Williams JP, Cook WJ, McDonald JM. Requirement of calmodulin binding by HIV-1 gp160 for enhanced FAS-mediated apoptosis. J Biol Chem 2000; 275: 1233-1240.
7. Micoli KJ, Mamaeva O, Piller SC, Barker JL, Pan G, Hunter E, McDonald JM. Point mutations in the C-terminus of HIV-1 gp160 reduce apoptosis and calmodulin binding without affecting viral replication. Virology 2006; 344: 468-479.
8. Srinivas SK, Srinivas RV, Anantharamaiah GM, Compans RW, Segrest JP. Cytosolic domain of the human-immunodeficiency-virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins. J Biol Chem 1993; 268: 22895-22899.
9. Shacklett BL, Weber CJ, Shaw KES, Keddie EM, Gardner MB, Sonigo P, Luciw PA. The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques. J Virol 2000; 74: 5836-5844.
10. Radding W, Williams JP, McKenna MA, Tummala R, Hunter E, Tytler EM, McDonald JM. Calmodulin and HIV type 1: interactions with gag and gag products. AIDS Res Hum Retroviruses 2000; 16: 1519-1525.
11. De Francesco MA, Baronio M, Fiorentini S, Signorini C, Bonfanti C, Poiesi C, Popovic M, Grassi M, Garrafa E, Bozzo L, Lewis GK, Licenziati S, Gallo RC, Caruso A. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci USA 2002; 99: 9972-9977.
12. Ghanam RH, Fernandez TF, Fledderman EL, Saad JS. Binding of calmodulin to the HIV-1 matrix protein triggers myristate exposure. J Biol Chem 2010; 285: 41911-41920.
13. Perlman M, Resh MD. Identification of an intracellular trafficking and assembly pathway for HIV-1 gag. Traffic 2006; 7: 731-745.
14. Swanson CM, Malim MH. SnapShot: HIV-1 proteins. Cell 2008; 133: 798.
15. Matsubara M, Tao J, Kawamura K, Shimojo N, Titani K, Hashimoto K, Hayashi N. Myristoyl moiety of HIV Nef is involved in regulation of the interaction with calmodulin in vivo. Protein Sci 2005; 14: 494-503.
16. Tomasselli aG, Howe WJ, Hui JO, Sawyer TK, Reardon IM, Decamp DL, Craik CS, Heinrikson RL. Calcium-free calmodulin is a substrate of proteases from human immunodeficiency virus-1 and virus-2. Proteins: Struct Funct Genet 1991; 10: 1-9.
17. Daube H, Billich a, Mann K, Schramm HJ. Cleavage of phosphorylase-kinase and calcium-free calmodulin by HIV-1 protease. Biochem Biophys Res Commun 1991; 178: 892-898.
18. Arya SK, Guo C, Josephs SF, Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985; 229: 69-73.
19. Shojania S, O'Neil JD. Intrinsic disorder and function of the HIV-1 Tat protein. Protein Pept Lett 2010; 17: 999-1011.
20. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription. Tat J Biol Chem 1999; 274: 28837-28840.
21. Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J, Handa H. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 1999; 97: 41-51.
22. Bourgeois CF, Kim YK, Churcher MJ, West MJ, Karn J. Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences. Mol Cell Biol 2002; 22: 1079-1093.
23. Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karn J. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 2002; 22: 4622-4637.
24. Neuveut C, Jeang KT. Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. J Virol 1996; 70: 5572-5581.
25. Kuppuswamy M, Subramanian T, Srinivasan A, Chinnadurai G. Multiple functional domains of Tat, the trans-activator of HIV-1. Mutat Anal Nucl Acids Res 1989; 17: 3551-3561.
26. Garcia Ja, Harrich D, Pearson L, Mitsuyasu R, Gaynor RB. Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J 1988; 7: 3143-3147.
27. Smith SM, Pentlicky S, Klase Z, Singh M, Neuveut C, Lu CY, Reitz MS Jr, Yarchoan R, Marx PA, Jeang KT. An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. J Biol Chem 2003; 278: 44816-44825.
28. Mahlknecht U, Dichamp I, Varin A, Van Lint C, Herbein G. NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. J Leukoc Biol 2008; 83: 718-727.
29. Shojania S, O'Neil JD. HIV-1 Tat is a natively unfolded protein-the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy. J Biol Chem 2006; 281: 8347-8356.
30. Anand K, Schulte A, Fujinaga K, Scheffzek K, Geyer M. Cyclin box structure of the P-TEFb subunit cyclin T1 derived from a fusion complex with EIAV Tat. J Mol Biol 2007; 370: 826-836.
31. Anand K, Schulte A, Vogel-Bachmayr K, Scheffzek K, Geyer M. Structural insights into the Cyclin T1-Tat-TAR RNA transcription activation complex from EIAV. Nature Struct Mol Biol 2008; 15: 1287-1292.
32. Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 2010; 465: 747-751.
33. Foucault M, Mayol K, Receveur-Bréchot V, Bussat MC, Klinguer-Hamour C, Verrier B, Beck A, Haser R, Gouet P, Guillon C. UV and X-ray structural studies of a 101-residue long Tat protein from a HIV-1 primary isolate and of its mutated, detoxified, vaccine candidate. Proteins: Struct Funct Bioinform 2010; 78: 1441-1456.
34. Vendel AC, Lumb KJ. Molecular recognition of the human coactivator CBP by the HIV-1 transcriptional activator Tat. Biochemistry 2003; 42: 910-916.
35. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J 1998; 17: 7056-7065.
36. Chen D, Wang M, Zhou S, Zhou Q. HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. EMBO J 2002; 21: 6801-6810.
37. Campbell GR, Pasquier E, Watkins J, Bourgarel-Rey V, Peyrot V, Esquieu D, Barbier P, de Mareuil J, Braguer D, Kaleebu P, Yirrell DL, Loret EP. The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem 2004; 279: 48197-48204.
38. Weeks KM, Ampe C, Schultz SC, Steitz TA, Crothers DM. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 1990; 249: 1281-1285.
39. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 2005; 57: 637-651.
40. Cardarelli F, Serresi M, Bizzarri R, Beltram F. Tuning the transport properties of HIV-1 tat arginine-rich motif in living cells. Traffic 2008; 9: 528-539.
41. Derse D, Carvalho M, Carroll R, Peterlin BM. A minimal lentivirus Tat. J Virol 1991; 65: 7012-7015.
42. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005; 62: 1839-1849.
43. Alimonti JB, Ball TB, Fowke KR. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 2003; 84 (Part 7): 1649-1661.
44. Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci USA 1999; 96: 8324-8326.
45. Pocernich CB, Sultana R, Mohmmad-Abdul H, Nath A, Butterfield DA. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res Brain Res Rev 2005:50.
46. Mattson MP, Haughey NJ, Nath A. Cell death in HIV dementia. Cell Death and Differentiation 2005; 12: 893-904.
47. Singla SI, Hudmon A, Goldberg JM, Smith JL, Schulman H. Molecular characterization of calmodulin trapping by calcium/calmodulin-dependent protein kinase II. J Biol Chem 2001; 276: 29353-29360.
48. Gopalakrishna R, Anderson WB. Ca2+-induced hydrophobic site on calmodulin: application for purification of calmodulin by phenyl-Sepharose affinity chromatography. Biochem Biophys Res Commun 1982; 104: 830-836.
49. Kincaid RL, Billingsley ML, Vaughan M. Preparation of fluorescent, cross-linking, and biotinylated calmodulin derivatives and their use in studies of calmodulin-activated phosphodiesterase and protein phosphatase. Methods Enzymol 1988; 159: 605-626.
50. Wu CS, Chen GC. Adsorption of proteins onto glass surfaces and its effect on the intensity of circular dichroism spectra. Anal Biochem 1989; 177: 178-182.
51. Donald LJ, Duckworth HW, Standing KG. Mass Spectrometry in noncovalent protein interactions and protein assemblies. In: Celis J, Simons K, Small JV, Hunter T, Shotton D, editors. Cell biology-a laboratory handbook, 3rd ed., Vol. 4. San Diego: Elsevier Academic Press; 2006. pp 457-464.
52. Kozlovski KI DL, Montero-Collado V, Loboda AV, Chernushevich IV, Ens W, Standing KG. TOF Mass spectrometer with ESI source, orthogonal injection, and 16 kV acceleration voltage, for study of noncovalent complexes. San Antonio, Texas: American Society for Mass Spectrometry; 2005. p 03:20.
53. Loboda AV, Krutchinsky AN, Bromirski M, Ens W, Standing KG. A tandem quadrupole/time-of-flight mass spectrometer with a matrix-assisted laser desorption/ionization source: design and performance. Rapid Commun Mass Spectrometry 2000; 14: 1047-1057.
54. Kay LE, Keifer P, Saarinen T. Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. J Am Chem Soc 1992; 114: 10663-10665.
55. Cavanagh JF, Wayne J, Palmer AGIII, Skelton NJ. Protein NMR spectroscopy: principles and practise. San Diego: Academic Press; 1996.
56. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 1995; 6: 277-293.
57. Farrow NA, Muhandiram R, Singer AU, Pascal SM, Kay CM, Gish G, Shoelson SE, Pawson T, Forman-Kay JD, Kay LE. Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. Biochemistry 1994; 33: 5984-6003.
58. Shaka AJ, Keeler J, Frenkiel T, Freeman R. An improved sequence for broad-band decoupling-Waltz-16. J Magn Reson 1983; 52: 335-338.
59. Wishart DS, Bigam CG, Yao J, Abildgaard F, Dyson HJ, Oldfield E, Markley JL, Sykes BD. 1H, 13C and 15N chemical shift referencing in biomolecular NMR. J Biomol NMR 1995; 6: 135-140.
60. Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, Korber B, editors. HIV sequence compendium 2005. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM; 2005.
61. Yap KL, Kim J, Truong K, Sherman M, Yuan T, Ikura M. Calmodulin target database. J Struct Funct Genomics 2000; 1: 8-14.
62. Radding W, Williams JP, McKenna MA, Tummala R, Hunter E, Tytler EM, McDonald JM. Calmodulin and HIV type 1: interactions with Gag and Gag products. AIDS Res Hum Retroviruses 2000; 16: 1519-1525.
63. Fasman GD. Distinguishing transmembrane helices from peripheral helices by circular dichrosim. Biotechnol Appl Biochem 1993; 18 (Part 2): 111-138.
64. Zhou Y, Yang W, Lurtz MM, Ye Y, Huang Y, Lee HW, Chen Y, Louis CF, Yang JJ. Identification of the calmodulin binding domain of connexin 43. J Biol Chem 2007; 282: 35005-35017.
65. Salerno JC, Harris DE, Irizarry K, Patel B, Morales AJ, Smith SM, Martasek P, Roman LJ, Masters BS, Jones CL, Weissman BA, Lane P, Liu Q, Gross SS. An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase. J Biol Chem 1997; 272: 29769-29777.
66. Ikura M, Kay LE, Bax a. A novel-approach for sequential assignment of H-1, C-13, and N-15 spectra of larger proteins-heteronuclear triple-resonance 3-dimensional NMR-spectroscopy-application to calmodulin. Biochemistry 1990; 29: 4659-4667.
67. Vandonselaar M, Hickie RA, Quail JW, Delbaere LT. Trifluoperazine-induced conformational change in Ca(2+)-calmodulin. Nat Struct Biol 1994; 1: 795-801.
68. Dyer MD, Murali TM, Sobral BW. The landscape of human proteins interacting with viruses and other pathogens. PLoS Pathogens 2008; 4: e32.
69. Fu W, Sanders-Beer BE, Katz KS, Maglott DR, Pruitt KD, Ptak RG. Human immunodeficiency virus type 1, human protein interaction database at NCBI. Nucleic Acids Res 2009; 37(Database issue): D417-D422.
70. Ptak RG, Fu W, Sanders-Beer BE, Dickerson JE, Pinney JW, Robertson DL, Rozanov MN, Katz KS, Maglott DR, Pruitt KD, Dieffenbach CW. Cataloguing the HIV-1 human protein interaction network. AIDS Res Hum Retroviruses 2008; 24: 1497-1502.
71. Pinney JW, Dickerson JE, Fu W, Sanders-Beer BE, Ptak RG, Robertson DL. HIV-host interactions: a map of viral perturbation of the host system. AIDS 2009; 23: 549-554.
72. Jeffery CJ. Moonlighting proteins-an update. Mol Bio Syst 2009; 5: 345-350.
73. Shifman JM, Mayo SL. Exploring the origins of binding specificity through the computational redesign of calmodulin. Proc Natl Acad Sci USA 2003; 100: 13274-13279.
74. Patil A, Kinoshita K, Nakamura H. Hub promiscuity in protein-protein interaction networks. Int J Mol Sci 2010; 11: 1930-1943.
75. Koonin EV, Wolf YI, Karev GP. The structure of the protein universe and genome evolution. Nature 2002; 420: 218-223.
76. Wilson MA, Brunger AT. The 1.0 A crystal structure of Ca(2+)-bound calmodulin: an analysis of disorder and implications for functionally relevant plasticity. J Mol Biol 2000; 301: 1237-1256.
77. Hahn KM, Kuhlman B. Hold me tightly LOV. Nat Methods 2010; 7: 595-597.
78. Persechini A, Stemmer PM. Calmodulin is a limiting factor in the cell. Trends Cardiovasc Med 2002; 12: 32-37.
79. Rakhilin SV, Olson PA, Nishi A, Starkova NN, Fienberg AA, Nairn AC, Surmeier DJ, Greengard P. A network of control mediated by regulator of calcium/calmodulin-dependent signaling. Science 2004; 306: 698-701.
80. Xia ZG, Storm DR. The role of calmodulin as a signal integrator for synaptic plasticity. Nature Rev Neurosci 2005; 6: 267-276.
81. Chen JW, Romero P, Uversky VN, Dunker AK. Conservation of intrinsic disorder in protein domains and families. I. A database of conserved predicted disordered regions. J Proteome Res 2006; 5: 879-887.
82. Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF, Jones DT. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 2004; 337: 635-645.
83. Gunasekaran K, Tsai CJ, Kumar S, Zanuy D, Nussinov R. Extended disordered proteins: targeting function with less scaffold. Trends Biochem Sci 2003; 28: 81-85.
84. Dunker AK, Cortese MS, Romero P, Iakoucheva LM, Uversky VN. Flexible nets-the roles of intrinsic disorder in protein interaction networks. FEBS J 2005; 272: 5129-5148.
85. Patil A, Kinoshita K, Nakamura H. Domain distribution and intrinsic disorder in hubs in the human protein-protein interaction network. Protein Sci 2010; 19: 1461-1468.
86. Mathur S, Badertscher M, Scott M, Zenobi R. Critical evaluation of mass spectrometric measurement of dissociation constants: accuracy and cross-validation against surface plasmon resonance and circular dichroism for the calmodulin-melittin system. Phys Chem Chem Phys 2007; 9: 6187-6198.
87. Newman RA, Van Scyoc WS, Sorensen BR, Jaren OR, Shea MA. Interdomain cooperativity of calmodulin bound to melittin preferentially increases calcium affinity of sites I and II. Proteins 2008; 71: 1792-1812.
88. Fisher PJ, Prendergast FG, Ehrhardt MR, Urbauer JL, Wand AJ, Sedarous SS, McCormick DJ, Buckley PJ. Calmodulin interacts with amphiphilic peptides composed of all D-amino acids. Nature 1994; 368: 651-653.
89. Tompa P. Intrinsically unstructured proteins. Trends Biochem Sci 2002; 27: 527-533.
90. Henzler-Wildman K, Kern D. Dynamic personalities of proteins. Nature 2007; 450: 964-972.
91. Baldwin AJ, Kay LE. NMR spectroscopy brings invisible protein states into focus. Nat Chem Biol 2009; 5: 808-814.
92. Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009; 4: 195-204.
93. Azizi A, Diaz-Mitoma F. Viral peptide immunogens: current challenges and opportunities. J Pept Sci 2007; 12: 776-786.
94. Kao DJ, Hodges RS. Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa. Chem Biol Drug Design 2009; 74: 33-42.
95. Moseri A, Tantry S, Sagi Y, Arshava B, Naider F, Anglister J. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Virology 2010; 401: 293-304.
96. Putkey JA, Waxham MN, Gaertner TR, Brewer KJ, Goldsmith M, Kubota Y, Kleerekoper QK. Acidic/IQ motif regulator of calmodulin. J Biol Chem 2008; 283: 1401-1410.
97. Barbato G, Ikura M, Kay LE, Pastor RW, Bax A. Backbone dynamics of calmodulin studied by 15N relaxation using inverse detected two-dimensional NMR spectroscopy: the central helix is flexible. Biochemistry 1992; 31: 5269-5278.
98. Izumi Y, Watanabe H, Watanabe N, Aoyama A, Jinbo Y, Hayashi N. Solution X-ray scattering reveals a novel structure of calmodulin complexed with a binding domain peptide from the HIV-1 matrix protein p17. Biochemistry 2008; 47: 7158-7166.
99. Sugita T, Yoshikawa T, Mukai Y, Yamanada N, Imai S, Nagano K, Yoshida Y, Shibata H, Yoshioka Y, Nakagawa S, Kamada H, Tsunoda SI, Tsutsumi Y. Comparative study on transduction and toxicity of protein transduction domains. Br J Pharmacol 2008; 153: 1143-1152.
100. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410: 988-994.
101. King JE, Eugenin EA, Buckner CM, Berman JW. HIV tat and neurotoxicity. Microbes Infect 2006; 8: 1347-1357.
102. Banks WA, Robinson SM, Nath A. Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 2005; 193: 218-227.
103. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, Geiger JD. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 1996; 70: 1475-1480.
104. Toborek M, Lee YW, Flora G, Pu H, András IE, Wylegala E, Hennig B, Nath A. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 2005; 25: 181-199.
105. Karn J. Tackling tat. J Mol Biol 1999; 293: 235-254.
106. Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripheral Nervous Syst 2001; 6: 21-27.
107. Ammosova T, Washington K, Debebe Z, Brady J, Nekhai S. Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription. Retrovirology 2005; 2: 1-15.
108. Zhou M, Halanski MA, Radonovich MF, Kashanchi F, Peng J, Price DH, Brady JN. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol 2000; 20: 5077-5086.
109. Chen RC, Liu M, Li H, Xue Y, Ramey WN, He NH, Ai NP, Luo HH, Zhu Y, Zhou N, Zhou Q. PP2B and PP1 alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev 2008; 22: 1356-1368.
110. Negulescu PA, Shastri N, Cahalan MD. Intracellular calcium dependence of gene expression in single T lymphocytes. Proc Natl Acad Sci USA 1994; 91: 2873-2877.
111. Poggi A, Carosio R, Rubartelli A, Zocchi MR. beta-mediated engulfment of apoptotic tumor cells by dendritic cells is dependent on CAMKII: inhibition by HIV-1 Tat. J Leukocyte Biol 2002; 71: 531-537.
112. Poggi A, Rubartelli A, Zocchi MR. Involvement of dihydropyridine-sensitive calcium channels in human dendritic cell function. J Biol Chem 1998; 273: 7205-7209.
113. Goh KC, Haque SJ, Williams BRG. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 1999; 18: 5601-5608.
114. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
115. Santella L, Ercolano E, Nusco GA. The cell cycle: a new entry in the field of Ca2+ signaling. Cell Mol Life Sci 2005; 62: 2405-2413.
116. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang LL, Li YZ, Pardee AB. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 1997; 94: 8116-8120.
117. Wang CM, Li N, Liu XG, Zheng YY, Cao XT. A novel endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest via p27 stabilization. J Biol Chem 2008; 283: 11565-11574.
118. Wang X, Kleerekoper QK, Xiong LW, Putkey JA. Intrinsically disordered PEP-19 confers unique dynamic properties to apo and calcium calmodulin. Biochemistry 2010; 49: 10287-10297.
119. McCloskey TW, Ott M, Tribble E, Khan SA, Teichberg S, Paul MO, Pahwa S, Verdin E, Chirmule N. Dual role of HIV Tat in regulation of apoptosis in T cells. J Immunol 1997; 158: 1014-1019.
120. Wayman GA, Lee YS, Tokumitsu H, Silva AJ, Soderling TR. Calmodulin-kinases: modulators of neuronal development and plasticity. Neuron 2008; 59: 914-931.